fresco-2: phase iii study of fruquintinib in patients with mcrc
Published 3 years ago • 365 plays • Length 4:48Download video MP4
Download video MP3
Similar videos
-
2:05
fruquintinib vs. placebo in mcrc: q-twist analysis from fresco-2
-
3:15
investigating fruquintinib in patients with refractory metastatic crc
-
3:35
#esmo22 highlights on the efficacy and safety of fruquintinib in refractory mcrc: the fresco-2 study
-
3:06
evaluating the role of fruquintinib in patients with refractory mcrc
-
0:44
implications of the post-hoc q-twist analysis of fruquintinib in refractory mcrc
-
9:05
fresco-2: analyzing fruquintinib for refractory metastatic colorectal cancer
-
2:27
fruquintinib in treating metastatic colorectal cancer
-
1:30
how will fruquintinib fit in the colorectal cancer treatment landscape?
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
5:31
非凡好健康 17-7 大腸癌
-
17:41
felix 2.0: where we are, where we are going - part 1
-
4:24
dr. cathy eng discusses fresco-2 trial and fruquintinib for colorectal cancer
-
3:33
fruquintinib provides improvement in overall survival for refractory mcrc
-
9:41
dr. cathy eng discusses the fresco-2 study and its impact on metastatic colorectal cancer treatment
-
2:39
patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
-
1:24
positive results& remaining questions in the fresco-2 study of colorectal cancer: 2022 esmo florida
-
1:11
advances in colorectal cancer therapies at esmo 2023
-
1:47
new treatment option for metastatic colorectal cancer prolongs survival
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
2:51
sirflox: results of the phase iii trial in mcrc
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc